EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to shield bone marrow in tough lung cancer cases
Disease control Recruiting nowThis phase II trial tests whether giving trilaciclib before sacituzumab tirumotecan can protect bone marrow in patients with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard treatments. About 49 participants will receive the drug combo and …
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill shows promise against tough lung cancer mutations
Disease control Recruiting nowThis study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a salt substitute save your kidneys after tumor surgery?
Disease control Recruiting nowThis study tests whether using a low-sodium, potassium-enriched salt substitute instead of regular salt can help protect kidney function in people who have had surgery for a kidney tumor. Two hundred adults who had a partial or full kidney removal will either use the salt substit…
Matched conditions: EGFR
Phase: NA • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for lung cancer patients whose drugs have failed
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy for lung cancer under Real-World watch
Knowledge-focused Recruiting nowThis observational study follows 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers will collect medical data to see how long the tr…
Matched conditions: EGFR
Sponsor: GFPC Investigation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC